LERCADIP 10 MG FILM COATED TABLETS
Active substance(s): LERCANIDIPINE HYDROCHLORIDE
NAME OF THE MEDICINAL PRODUCT
Lercadip 10 mg film-coated tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 10 mg lercanidipine hydrochloride (equivalent to
9.4 mg lercanidipine).
Excipient(s) with known effect:
One film-coated tablet contains 30 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
Yellow, circular, biconvex tablets, scored on one side.
The score lines is only to facilitate breaking for ease of swallowing and not to
divide into equal doses.
Lercadip is indicated in adults for the treatment of mild to moderate essential
Posology and method of administration
The recommended dosage is 10 mg orally once a day at least 15 minutes before
meals; the dose may be increased to 20 mg depending on the individual patient's
Dose titration should be gradual, because it may take about 2 weeks before the
maximal antihypertensive effect is apparent.
Some individuals, not adequately controlled on a single antihypertensive agent,
may benefit from the addition of LERCADIP to therapy with a beta-adrenoceptor
blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin
converting enzyme inhibitor (captopril or enalapril).
Since the dose-response curve is steep with a plateau at doses between 20-30 mg, it
is unlikely that efficacy will be improved by higher doses; whereas side effects may
Older patients: although the pharmacokinetic data and clinical experience suggest
that no adjustment of the daily dosage is required, special care should be exercised
when initiating treatment in the elderly.
Patients with renal or hepatic impairment: special care should be exercised when
treatment is commenced in patients with mild to moderate renal or hepatic
dysfunction. Although the usually recommended dose schedule may be tolerated by
these subgroups, an increase in dose to 20 mg daily must be approached with
caution. The antihypertensive effect may be enhanced in patients with hepatic
impairment and consequently an adjustment of the dosage should be considered.
LERCADIP is not recommended for use in patients with severe hepatic impairment
or in patients with severe renal impairment (GFR < 30 ml/min).
The safety and efficacy of LERCADIP in children aged up to 18 years have not
No data are available.
Method of administration
For oral use.
Precautions to be taken before handling or administering the medicinal product:
- Treatment should be preferably administered in the morning at least 15 minutes
- This product should not been administered with grapefruit juice (see section 4.3
Hypersensitivity to the active substance or to any of the excipients listed in
Pregnancy and lactation (see section 4.6).
Women of child-bearing potential unless effective contraception is used
Left ventricular outflow tract obstruction.
Untreated congestive cardiac failure.
Unstable angina pectoris.
Severe renal or hepatic impairment.
Within 1 month of a myocardial infarction.
o strong inhibitors of CYP3A4 (see section 4.5),
o cyclosporin (see section 4.5),
o grapefruit and grapefruit juice (see section 4.5).
Special warnings and precautions for use
Special care should be exercised when LERCADIP is used in patients with sick
sinus syndrome (without a pacemaker).
Left ventricular dysfunction and ischaemic heart disease
Although hemodynamic controlled studies revealed no impairment of ventricular
function, care is also required in patients with LV dysfunction. It has been
suggested that some short-acting dihydropyridines may be associated with
increased cardiovascular risk in patients with ischaemic heart disease. Although
LERCADIP is long-acting caution is required in such patients.
Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very
rarely patients with pre-existing angina pectoris may experience increased
frequency, duration or severity of these attacks. Isolated cases of myocardial
infarction may be observed (see section 4.8).
Patients with renal or hepatic impairment
Special care should be exercised when treatment is commenced in patients with
mild to moderate renal or hepatic dysfunction. Although the usually recommended
dose schedule may be tolerated by these subgroups, an increase in dose to 20 mg
daily must be approached with caution. The antihypertensive effect may be
enhanced in patients with hepatic impairment and consequently an adjustment of
the dosage should be considered.
LERCADIP is not recommended for use in patients with severe hepatic impairment
or in patients with severe renal impairment (GFR < 30 ml/min) (see section 4.2).
Inducers of CYP3A4
Inducers of CYP3A4 like anticonvulsants (e.g. phenytoin, carbamazepine) and
rifampicin may reduce lercanidipine’s plasma levels and therefore the efficacy of
lercanidipine may be less than expected (see section 4.5).
Alcohol should be avoided since it may potentiate the effect of vasodilating
antihypertensive drugs (see section 4.5).
One tablet contains 30 mg lactose and therefore should not be administered to
patients with Lapp lactase insufficiency, galactosaemia or glucose/galactose
The safety and efficacy of Lercadip have not been demonstrated in children and
adolescents aged up to 18 years.
Interaction with other medicinal products and other forms of interaction
Inhibitors of CYP3A4
Lercanidipine is known to be metabolised by the CYP3A4 enzyme and, therefore,
inhibitors and inducers of CYP3A4 administered concurrently may interact with the
metabolism and elimination of lercanidipine.
Co-prescription of LERCADIP with inhibitors of CYP3A4 (e.g. ketoconazole,
itraconazole, ritonavir, erythromycin, troleandomycin) should be avoided (see
An interaction study with a strong CYP3A4 inhibitor, ketoconazole, has shown a
considerable increase in plasma levels of lercanidipine (a 15-fold increase of the
AUC and an 8-fold increase of the Cmax for the eutomer S-lercanidipine).
Cyclosporin and lercanidipine should not be administered together (see section 4.3).
Increased plasma levels of both lercanidipine and cyclosporin have been observed
following concomitant administration. A study in young healthy volunteers has
shown that when cyclosporin was administered 3 hours after the lercanidipine
intake, the plasma levels of lercanidipine did not change, while the AUC of
cyclosporin increased by 27%. However, the co-administration of LERCADIP with
cyclosporin has caused a 3-fold increase of the plasma levels of lercanidipine and a
21% increase of the cyclosporin AUC.
Lercanidipine should not be taken with grapefruit and grapefruit juice (see section
As for other dihydropyridines, lercanidipine is sensitive to inhibition of metabolism
by grapefruit juice, with a consequent rise in its systemic availability and increased
When concomitantly administered at a dose of 20 mg with midazolam p.o. to
elderly volunteers, lercanidipine’s absorption was increased (by approximately
40%) and the rate of absorption was decreased (tmax was delayed from 1.75 to 3
hours). Midazolam concentrations were not modified.
Substrates of CYP3A4
Caution should be exercised when LERCADIP is co-prescribed with other
substrates of CYP3A4, like terfenadine, astemizole, class III antiarrhythmic drugs
such as amiodarone, quinidine.
Inducers of CYP3A4
Co-administration of LERCADIP with CYP3A4 inducers like anticonvulsants (e.g.
phenytoin, carbamazepine) and rifampicin should be approached with caution since
the antihypertensive effect may be reduced and blood pressure should be monitored
more frequently than usual.
When LERCADIP was co-administered with metoprolol, a β-blocker eliminated
mainly by the liver, the bioavailability of metoprolol was not changed while that of
lercanidipine was reduced by 50%. This effect may be due to the reduction in the
hepatic blood flow caused by β-blockers and may therefore occur with other drugs
of this class. Consequently, lercanidipine may be safely administered with betaadrenoceptor blocking drugs, but dose adjustment may be required.
An interaction study with fluoxetine (an inhibitor of CYP2D6 and CYP3A4),
conducted in volunteers of an age of 65 ± 7 years (mean ± s.d.), has shown no
clinically relevant modification of the pharmacokinetics of lercanidipine.
Concomitant administration of cimetidine 800 mg daily does not cause significant
modifications in plasma levels of lercanidipine, but at higher doses caution is
required since the bioavailability and the hypotensive effect of lercanidipine may be
Co-administration of 20 mg lercanidipine in patients chronically treated with βmethyldigoxin showed no evidence of pharmacokinetic interaction. Healthy
volunteers treated with digoxin following dosing with 20 mg lercanidipine given
fasted showed a mean increase of 33% in digoxin Cmax, while AUC and renal
clearance were not significantly modified. Patients on concomitant digoxin
treatment should be closely monitored clinically for signs of digoxin toxicity.
When a dose of 20 mg of LERCADIP was repeatedly co-administered with 40 mg
of simvastatin, the AUC of lercanidipine was not significantly modified, while
simvastatin’s AUC increased by 56% and that of its active metabolite βhydroxyacid by 28%. It is unlikely that such changes are of clinical relevance. No
interaction is expected when lercanidipine is administered in the morning and
simvastatin in the evening, as indicated for such drug.
The co-administration of 20 mg lercanidipine to healthy volunteers given fasted did
not alter the pharmacokinetics of warfarin.
Diuretics and ACE inhibitors
LERCADIP has been safely administered with diuretics and ACE inhibitors.
Alcohol should be avoided since it may potentiate the effect of vasodilating
antihypertensive drugs (see section 4.4).
Interaction studies have only been performed in adults.
Fertility, pregnancy and lactation
Data for lercanidipine provide no evidence of a teratogenic effect in the rat and the
rabbit and reproductive performance in the rat was unimpaired. Nevertheless, since
there is no clinical experience with lercanidipine in pregnancy and lactation, and
other dihydropyridine compounds have been found teratogenic in animals,
LERCADIP should not be administered during pregnancy or to women with childbearing potential unless effective contraception is used.
It is unknown whether lercanidipine/metabolites are excreted in human milk. A risk
in the newborns/infants cannot be excluded. LERCADIP is contraindicated during
breastfeeding (see section 4.3) .
No clinical data are available with lercanidipine. Reversible biochemical changes in
the head of spermatozoa which can impair fecundation have been reported in some
patients treated by calcium channel blockers. In cases where repeated in-vitro
fertilisation is unsuccessful and where another explanation cannot be found, the
possibility of calcium channel blockers as the cause should be considered.
Effects on ability to drive and use machines
LERCADIP has minor influence on the ability to drive and use machines. However,
caution should be exercised because dizziness, asthenia, fatigue and rarely
somnolence may occur.
About 1.8% of treated patients experienced adverse reactions.
The table below shows the incidence of adverse drug reactions, at least
possibly causally related, grouped by MedDRA System Organ Class
classification and ranked by frequency: very common (≥1/10); common
(≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
<1/1,000); very rare (<1/10,000), not known (frequency cannot be estimated
from available data). Within each frequency grouping the observed adverse
reactions are presented in order of decreasing seriousness.
As shown in the table, the most commonly occurring adverse drug reactions
reported in controlled clinical trials are headache, dizziness, peripheral
oedema, tachycardia, palpitations, flushing, each occurring in less than 1%
Spontaneous reports from the post-marketing experience are grouped under
the “not known” frequency category.
Some dihydropyridines may lead to precordial pain or angina pectoris.
Patients with pre-existing angina pectoris may experience increased
frequency, duration or severity of these attacks. Cases of myocardial
infarction may be observed.
Lercanidipine does not appear to influence blood sugar or serum lipid levels.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk
balance of the medicinal product. Healthcare professionals are asked to
report any suspected adverse reactions via the Yellow Card Scheme at
In the post-marketing experience, some cases of overdose were reported
(from 40 up to 800 mg of lercanidipine, including reports of suicide
As with other dihydropyridines, overdosage might be expected to cause
excessive peripheral vasodilatation. Symptoms associated to overdose
include marked hypotension, dizziness, fatigue and reflex tachycardia.
Cardiac failure, myocardial ischaemia and acute renal failure might occur. In
case of severe hypotension cardiovascular support could be helpful.
In view of the prolonged pharmacological effect of lercanidipine, it is
essential that the cardiovascular status of patients who take an overdose is
monitored for 24 hours at least. There is no information on the value of
dialysis. Since the drug is highly lipophilic, it is most probable that plasma
levels are no guide to the duration of the period of risk and dialysis may not
Pharmacotherapeutic group: Selective calcium channel blockers with mainly
vascular effects –Dihydropyridine derivatives.
ATC code: C08CA13
Mechanism of action
Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the
transmembrane influx of calcium into cardiac and smooth muscle. The mechanism
of its antihypertensive action is due to a direct relaxant effect on vascular smooth
muscle thus lowering total peripheral resistance.
Despite its short pharmacokinetic plasma half-life, lercanidipine is endowed with a
prolonged antihypertensive activity because of its high membrane partition
coefficient, and is devoid of negative inotropic effects due to its high vascular
Since the vasodilatation induced by LERCADIP is gradual in onset, acute
hypotension with reflex tachycardia has rarely been observed in hypertensive
As for other asymmetric 1,4-dihydropyridines, the antihypertensive activity of
lercanidipine is mainly due to its (S)-enantiomer.
Clinical efficacy and safety
In addition to the clinical studies conducted to support the therapeutic indications, a
further small uncontrolled but randomised study of patients with severe
hypertension (mean + SD diastolic blood pressure of 114.5 + 3.7 mmHg) showed
that blood pressure was normalised in 40% of the 25 patients on 20 mg once daily
dose and in 56% of 25 patients on 10 mg twice daily doses of LERCADIP. In a
double-blind, randomized, controlled study versus placebo in patients with isolated
systolic hypertension LERCADIP was efficacious in lowering systolic blood
pressure from mean initial values of 172.6 + 5.6 mmHg to 140.2 + 8.7 mmHg.
LERCADIP is completely absorbed after 10-20 mg oral administration and peak
plasma levels, 3.30 ng/ml + 2.09 s.d. and 7.66 ng/ml + 5.90 s.d. respectively, occur
about 1.5-3 hours after dosing.
The two enantiomers of lercanidipine show a similar plasma level profile: the time
to peak plasma concentration is the same, the peak plasma concentration and AUC
are, on average, 1.2-fold higher for the (S) enantiomer and the elimination halflives of the two enantiomers are essentially the same. No "in vivo" interconversion
of enantiomers is observed.
Due to the high first pass metabolism, the absolute bioavailability of LERCADIP
orally administered to patients under fed conditions is around 10%, although it is
reduced to 1/3 when administered to healthy volunteers under fasting conditions.
Oral availability of lercanidipine increases 4-fold when LERCADIP is ingested up
to 2 hours after a high fat meal. Accordingly, LERCADIP should be taken before
Distribution from plasma to tissues and organs is rapid and extensive.
The degree of serum protein binding of lercanidipine exceeds 98%. Since plasma
protein levels are reduced in patients with severe renal or hepatic dysfunction, the
free fraction of the drug may be increased.
LERCADIP is extensively metabolised by CYP3A4; no parent drug is found in the
urine or the faeces. It is predominantly converted to inactive metabolites and about
50% of the dose is excreted in the urine.
“In vitro” experiments with human liver microsomes have demonstrated that
lercanidipine shows some degree of inhibition of CYP3A4 and CYP2D6, at
concentrations 160- and 40-fold, respectively, higher than those reached at peak in
the plasma after the dose of 20 mg.
Moreover, interaction studies in humans have shown that lercanidipine did not
modify the plasma levels of midazolam, a typical substrate of CYP3A4, or of
metoprolol, a typical substrate of CYP2D6. Therefore, inhibition of
biotransformation of drugs metabolised by CYP3A4 and CYP2D6 by LERCADIP
is not expected at therapeutic doses.
Elimination occurs essentially by biotransformation.
A mean terminal elimination half life of 8-10 hours was calculated and the
therapeutical activity lasts for 24 hours because of its high binding to lipid
membrane. No accumulation was seen upon repeated administration.
Oral administration of LERCADIP leads to plasma levels of lercanidipine not
directly proportional to dosage (non-linear kinetics). After 10, 20 or 40 mg, peak
plasma concentrations observed were in the ratio 1:3:8 and areas under plasma
concentration-time curves in the ratio 1:4:18, suggesting a progressive saturation of
first pass metabolism. Accordingly, availability increases with dosage elevation.
Additional information on special populations In elderly patients and in patients
with mild to moderate renal dysfunction or mild to moderate hepatic impairment
the pharmacokinetic behaviour of lercanidipine was shown to be similar to that
observed in the general patient population; patients with severe renal dysfunction or
dialysis-dependent patients showed higher levels (about 70%) of the drug. In
patients with moderate to severe hepatic impairment, the systemic bioavailability of
lercanidipine is likely to be increased since the drug is normally metabolised
extensively in the liver.
Pre-clinical safety data
Non-clinical data reveal no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity,carcinogenic potential, toxicity to reproduction.
Safety pharmacological studies in animals have shown no effects on the
autonomic nervous system, the central nervous system or on gastrointestinal
function at antihypertensive doses.
The relevant effects which have been observed in long-term studies in rats
and dogs were related, directly or indirectly, to the known effects of high
doses of Ca-antagonists, predominantly reflecting exaggerated
Lercanidipine was not genotoxic and showed no evidence of carcinogenic
Fertility and general reproductive performance in rats were unaffected by
treatment with lercanidipine.
There was no evidence of any teratogenic effect in rats and rabbits; however,
in rats, lercanidipine at high dose levels induced pre- and post- implantation
losses and delay in foetal development.
Lercanidipine hydrochloride, when administered at high dose (12
mg/kg/day) during labour, induced dystocia.
The distribution of lercanidipine and/or its metabolites in pregnant animals
and their excretion in breast milk have not been investigated.
Metabolites have not been evaluated separately in toxicity studies.
List of excipients
Sodium starch glycolate
Titanium dioxide (E171)
Ferric oxide (E172)
Special precautions for storage
Store in the original package in order to protect from light.
Nature and contents of container
Aluminium/opaque PVC blisters.
Packs of 7, 14, 28, 35, 50, 56, 98 and 100 tablets. **Not all pack sizes may be
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance
with local requirements.
MARKETING AUTHORISATION HOLDER
RECORDATI Industria Chimica e Farmaceutica S.p.A.
Via M. Civitali, 1 – 20148 Milan - Italy
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
Date of first authorisation: 27th October 2005
Date of latest renewal:
DATE OF REVISION OF THE TEXT